awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7
Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlle
P2860
Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8fa3391ae89373b9a31238a13eb6eb4b4092f91b
P2860
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes